Abstract: Various aspects of the present disclosure are directed toward apparatuses, systems, and methods that include a prosthetic valve. The prosthetic valve may include a jacket configured to cover at least one of gaps, spaces, or interfaces in a frame or between one or more leaflets attached to the frame.

Abstract: The present disclosure relates to systems and method for deploying a fiber optic network. Distribution devices are used to index fibers within the system to ensure that live fibers are provided at output locations throughout the system. In an example, fibers can be indexed in multiple directions within the system. In an example, spare ports can be providing in a forward direction and reverse direction ports can also be provided.

Abstract: An embodiment of a storage device for medical products includes a cabinet defining an enclosure having a plurality of compartments. In addition, the storage device includes a plurality of storage containers, each storage container configured to be inserted into a corresponding one of the plurality of compartments. Further, the storage device includes an actuation assembly including a plurality of arms that are configured to engage the plurality of storage containers so as to secure the plurality of storage containers in the plurality of compartments. Still further, the storage device includes a release mechanism that is configured to simultaneously actuate each of the plurality of arms to release the plurality of storage containers from the plurality of compartments.

Abstract: Fuses can store different delay states to cause execution of a command to be staggered for different memory dies of a memory package. Fuse arrays can be included in the memory package and programmed to cause execution of a command to be delayed by different amounts for different dies. The fuse arrays can be fabricated and then programmed to cause different delays for different dies.

Abstract: This invention relates to the preparation of N-(phosphonomethyl)glycine (“glyphosate”) from N-(phosphonomethyl)iminodiacetic acid (“PMIDA”), and more particularly to methods for control of the conversion of PMIDA, for the identification of reaction end points relating to PMIDA conversion and the preparation of glyphosate products having controlled PMIDA content.

Abstract: A therapy system includes a patient support apparatus and a pneumatic therapy device that is coupleable to the patient support apparatus. The therapy device may receive power and air flow from the patient support apparatus.

Abstract: An antimicrobial spray composition is disclosed, forming a protective film on surfaces when dried. The protective film provides antimicrobial protection by killing at least 95% of microorganisms in <30 minutes of exposure. The spray composition comprises a sulfonated polymer selected from the group of perfluorosulfonic acid polymers, polystyrene sulfonates, sulfonated block copolymers, sulfonated polyolefins, sulfonated polyimides, sulfonated polyamides, sulfonated polyesters, sulfonated polysulfones, sulfonated polyketones, sulfonated poly(arylene ether), and mixtures thereof.

Abstract: An air filter device. The air filter device comprises: a filter medium having an inlet surface for taking in air, and a discharge surface for filtered air. The filter medium having a plurality of air passages for the air to flow therethrough. At least a portion of the inlet surface of the filter medium comprises a sulfonated polymer for killing at least 90% microbes in the air within 120 minutes of contact with the surface of the air passages. The sulfonated polymer is selected from the group of perfluorosulfonic acid polymers, polystyrene sulfonates, sulfonated block copolymers, sulfonated polyolefins, sulfonated polyimides, sulfonated polyamides, sulfonated polyesters, sulfonated polysulfones, sulfonated polyketones, sulfonated poly(arylene ether), and mixtures thereof. The sulfonated polymer has a degree of sulfonation of at least 10%.

Abstract: An antimicrobial paint is disclosed. The antimicrobial paint comprises a carrier fluid, a binder, a sulfonated polymer and optionally at least an additive. The sulfonated polymer is selected from the group of perfluorosulfonic acid polymers, polystyrene sulfonates, sulfonated block copolymers, sulfonated polyolefins, sulfonated polyimides, sulfonated polyamides, sulfonated polyesters, sulfonated polysulfones such as polyether sulfone, sulfonated polyketones such as polyether ketone, sulfonated poly(arylene ether), and mixtures thereof. The sulfonated polymer is sufficiently or selectively sulfonated to contain from 10-100 mol % sulfonic acid or sulfonate salt functional groups based on the number of monomer units, for killing at least 99% of microbes in less than 30 minutes, or in less than 5 minutes of coming into contact with a substrate coated in the antimicrobial paint composition.

Abstract: An overmolded/through-molded firearm magazine including at least some of one or more wall portions defining a magazine core, wherein the magazine core extends from a substantially open top portion to a substantially open bottom portion and at least partially defines a core cavity; at least one core aperture/recess formed through a portion of one or more of the one or more wall portions; and an overmolded body formed atop at least a portion of an exterior surface of the magazine core, wherein at least a portion of the overmolded body extends at least partially through the at least one core aperture/recess, forming a through-core protrusion.

Abstract: An overmolded/through-molded firearm magazine including at least some of one or more wall portions defining a magazine core, wherein the magazine core extends from a substantially open top portion to a substantially open bottom portion and at least partially defines a core cavity; at least one core aperture/recess formed through a portion of one or more of the one or more wall portions; and an overmolded body formed atop at least a portion of an exterior surface of the magazine core, wherein at least a portion of the overmolded body extends at least partially through the at least one core aperture/recess, forming a through-core protrusion.

Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.

Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.

Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.

Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.

Abstract: Disclosed is a method for the amelioration of osteophyte formation including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.

Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.

Abstract: The present invention provides for a high thermal conductivity (HTC) paper that comprises a host matrix, such as mica, and HTC materials intercalated into the host matrix. The HTC materials are comprised of at least one of nanofillers, diamond like coatings directly on the host matrix, and diamond like coatings on the nanofillers.

Abstract: Disclosed is a method for the amelioration of resorptive bone loss in osteopenia including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.

Abstract: Disclosed is a method for the amelioration of osteophyte formation including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.